All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Zedenoleucel (MT-401) granted orphan drug designation by the EMA

By Dylan Barrett

Share:

Jul 14, 2023

Learning objective: After reading this article, learners will be able to cite a new development in the treatment of AML.


On July 10, 2023, zedenoleucel (MT-401), a multi-tumor-associated antigen (multiTAA)-specific T-cell product, which was previously covered by the AML Hub, was granted orphan drug designation by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), for the treatment of patients with acute myeloid leukemia (AML).1 Zedenoleucel previously received orphan drug designation from the U.S. Food and Drug Administration (FDA) on April 29, 2020, for the treatment of patients with AML post-allogeneic hematopoietic stem cell transplantation.1

Zedenoleucel is a novel, non-genetically modified cell therapy that selectively expands a patient’s T cells to target multiple antigens expressed on tumor cells.1 Zedenoleucel is currently being investigated in a phase II clinical trial (NCT04511130) for the treatment of patients with relapsed AML who have undergone allogeneic hematopoietic stem cell transplantation.1 Promising initial results have been observed in this trial in patients with measurable residual disease, indicating that zedenoleucel has potential as a treatment for patients with AML prior to relapse.1

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content